This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Endocrine, Nutritional and Metabolic



October 2018

Apabetalone in addition to high-intensity statin therapy for preventing major adverse cardiac events in high-risk cardiovascular disease patients with type 2 diabetes mellitus

Apabetalone is the first product developed to inhibit BET proteins. These BET proteins can control the activity of cells and make them produce proteins that cause inflammation. By inhibiting the BET proteins the production of inflammatory proteins is reduced. Apabetalone also increases production of high density lipoproteins which removes excess cholesterol, reducing the risk of cardiovascular disease. Apabetalone has the potential to affect multiple processes which contribute to cardiovascular disease, with the overall result of reducing the risk of a major adverse cardiac event in diabetic patients. If licensed, apabetalone may offer an additional preventive treatment option for major adverse cardiac events in patients with type 2 diabetes mellitus, high-risk a high risk of cardiovascular disease and low HDL.


August 2018

Oral Semaglutide for the treatment of type 2 diabetes mellitus

Semaglutide works by increasing the amount of insulin released from the pancreas and by delaying how quickly food moves through your digestive system, which aid in controlling blood sugar levels. Semaglutide belongs to a class of antidiabetic medications called glucagon-like peptide 1 (GLP-1) receptor agonist. Most other medications in this class are administered by injection under the skin. If licensed, semaglutide will be the first effective oral GLP-1 analogue for the treatment of type 2 diabetes and may improve acceptance and adherence for some patients compared with the injectable formulation of GLP-1 receptor agonists.


May 2018

CER-001 for Familial Primary Hypoalphalipoproteinemia

CER-001 is an engineered complex of the major structural protein of HDL, in combination with key phospholipids. Administered through intravenous (IV) infusion, CER-001 mimics the structure and function of natural HDL to stimulate the removal of excess cholesterol and other lipids. There is currently limited treatment options available specifically for FPHA. If licensed, CER-001 may offer a new treatment option for FPHA by aiding in the transport and elimination of excess cholesterol and other lipids in the liver.


April 2018

Sodium thiosulfate for acute calciphylaxis-associated pain in chronic haemodialysis patients

Sodium thiosulfate is an injectable solution that is being developed to treat calciphylaxis-associated pain in patients undergoing dialysis. It is thought that sodium thiosulfate works by attaching itself to the calcium to form a compound that is removed from the body in the urine, reducing the build-up of calcium in the arteries. If licensed, this product will provide a treatment option for patients with calciphylaxis, who currently have few effective treatments available.



September 2017

Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus

Sotagliflozin is a drug being developed to lower blood sugar levels in type 1 diabetes by increasing the amount of sugars excreted in the urine. It is taken once a day tablet in conjunction with insulin to prevent large rises and falls in blood sugar levels. This may be especially useful for people who cannot …


September 2017

Setmelanotide for pro-opiomelanocortin deficiency obesity

Body fat and food intake are regulated by signals from the brain to the gut. One of the important hormones that is responsible for this is pro-opiomelanocortin (POMC). In a very small group of people there is a lack of this hormone (due to a genetic mutation), referred to as POMC deficiency. This causes severe …


July 2017

Arimoclomol for Niemann-Pick Disease type C – add-on therapy

Arimoclomol is a medicine that is under investigation as a treatment for NPC. It is given by mouth as capsules. Arimoclomol helps the body’s cells to process accumulated lipids. If licensed, arimoclomol could offer an additional treatment option for people with NPC.


March 2017

MiniMed™ 670G Hybrid Closed Loop system for type 1 diabetes

The MiniMed™ 670G system is a device to automatically deliver insulin for people with type 1 diabetes. Diabetes is a condition that causes a person’s blood sugar (glucose) level to become too high. Patients with type 1 diabetes do not produce enough insulin and they need regular insulin injections to keep their blood glucose levels …


February 2017

VTS-270 for Niemann-Pick disease type C1

VTS-270 is a new drug that is injected into the spine to treat Neimann-Pick disease, which is a rare genetic disorder that causes accumulation of fats in cells throughout the body, including the liver and the brain. It may lead to balance and learning difficulties and most patients do not survive beyond age 25. Some …

Get Alerts